NUAK1 and hepatocellular carcinoma: In this study, our findings revealed that NUAK1 can promote transcriptional expression of PD-L1 by activating the GSK3β/β-catenin signaling pathway, providing a novel strategy to improve the efficacy of PD-1/PD-L1 immunotherapy in HCC patients.